New Treatment For Advanced HER2+ Breast Cancer Patients As Perjeta® (Pertuzumab) Gets Regulatory Green Light
Perjeta works synergistically with Herceptin® (trastuzumab) to extend survival and stall disease progression for longer than the gold standard of care[i] From now on, patients with advanced HER2-positive breast cancer could benefit from the new personalised breast cancer treatment, Perjeta - which is now authorised for use in the UK. Perjeta has been granted a licence by the European Medicines Agency (EMA), for patients with previously untreated advanced HER2-positive breast cancer in combination with the current gold standard-of-care, Herceptin and chemotherapy (docetaxel)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Breast cancer drug 'biggest boost since Herceptin'
Thousands of women with a type of advanced breast cancer could benefit from a drug described as the biggest step-change in treatment of the disease since Herceptin was introduced in 1999. (Source: Telegraph Health)
Source: Telegraph Health - March 14, 2013 Category: Consumer Health News Tags: perjeta herceptin tumour roche breast cancer HER2 Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). PERJETA is approved in combination with Herceptin (trastuzumab) and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - March 5, 2013 Category: Pharmaceuticals Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). (Source: Roche Media News)
Source: Roche Media News - March 5, 2013 Category: Pharmaceuticals Source Type: news

Breast Cancer Stem Cells Express HER2, Even In 'Negative' Tumors, Study Finds
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative - and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. About 20 percent of women with breast cancer have tumors labeled HER2-positive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 28, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

HER2 Therapy Useful in More Than 20% of Breast CancersHER2 Therapy Useful in More Than 20% of Breast Cancers
The finding of HER2 in the small clump of cancer stems cells that drives the growth and spread of tumors suggests a wider use for drugs such as trastuzumab. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Herceptin 'could benefit thousands more women'
The highly effective breast cancer drug Herceptin could benefit thousands more women, according to a study which suggests it could stop the disease spreading in most patients if given early enough. (Source: Telegraph Health)
Source: Telegraph Health - February 26, 2013 Category: Consumer Health News Tags: herceptin michigan university cancer research breast cancer HER2 Source Type: news

Kadcyla Wins US FDA Approval for Late-Stage Breast Cancer
Ado-trastuzumab emtansine, a HER-2 targeted antibody-drug conjugate, has been approved by the U.S. Food and Drug Administration for treatment of women with HER2-positive, late-stage metastatic breast cancer,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 26, 2013 Category: Cancer & Oncology Source Type: news

U-M study challenges notion of using Herceptin only for HER2-positive breast cancer
(University of Michigan Health System) New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative -- and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2013 Category: Cancer & Oncology Source Type: news

Horizon scanning: US FDA approves ado-trastuzumab emtansine or T-DM1 (KadcylaT) for HER2-positive metastatic breast cancer
Source: BioSpace Area: News The US FDA has approved the antibody-drug conjugate ado-trastuzumab emtansine or T-DM1 (KadcylaT) for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with trastuzumab (Herceptin®) and a taxane.   KadcylaT, which is composed of the cytotoxic agent DM1 conjugated to trastuzumab, is the first antibody-drug conjugate to be approved by the FDA for the treatment of metastatic breast cancer. The approval was based on the results of the EMILIA Phase III study (n=991), which compared KadcylaT alone to lapatinib in combination with capec...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

Kadcyla Wins FDA Approval For HER2 Breast Cancer
A new drug will soon be available to treat HER2-positive metastatic breast cancer. Made by Genentech, it will be known as Kadcyla (ado-trastuzumab emtansine). This drug is a highly targeted ...Read Full Post (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 25, 2013 Category: Cancer & Oncology Source Type: news

FDA approves Genentech metastatic breast cancer drug
The US Food and Drug Administration (FDA) has approved Genentech's Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of HER2-positive metastatic breast cancer (mBC). (Source: Drug Development Technology)
Source: Drug Development Technology - February 25, 2013 Category: Pharmaceuticals Source Type: news

New drug OKd for late-stage breast cancer
WASHINGTON, Feb. 23 (UPI) -- The U.S. Food and Drug Administration approved Kadcyla, a new drug for patients with HER2-positive, late-stage or metastatic breast cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 24, 2013 Category: Consumer Health News Source Type: news

FDA OKs Genentech Breast Cancer Drug
(MedPage Today) -- A drug antibody conjugate called ado-trastuzumab emtansine (Kadcyla) received FDA approval Friday for HER2-positive, metastatic breast cancer. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 23, 2013 Category: Hematology Source Type: news

FDA Approves Kadcyla for Late-Stage Breast Cancer
February 22, 2013 -- The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. HER2 is a protein involved in normal cell growth.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Kadcyla For Late-Stage Breast Cancer Approved By FDA
Kadcyla (ado-trastuzumab emtansine), a new medication for the treatment of HER2-positive, metastatic breast cancer, has been approved by the Food and Drug Administration (FDA), USA. Metastatic, also known as late-stage, means the cancer has spread to other parts of the body. HER2, a protein which drives normal cell growth, is found in larger quantities in several kinds of cancer cells (HER2-positive), including a number of breast cancers. The HER2 protein contributes to the growth and survival of cancer cells in patients with HER2-positive breast cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

FDA Approves New Treatment for Metastatic HER2 Breast CancerFDA Approves New Treatment for Metastatic HER2 Breast Cancer
Trastuzumab emtansine, also known as T-DM1, provides clinicians with another treatment option for patients who progress on trastuzumab. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
New personalised medicine helped people in Phase III study live longer, compared to standard treatment (Source: Roche Media News)
Source: Roche Media News - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for late-stage breast cancer
The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 22, 2013 Category: American Health Source Type: news

FDA Approves T-DM1 (Kadcyla) for HER2-Positive Breast Cancer
The US Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla) for the treatment of patients with metastatic HER2-positive breast cancer earlier today. (Source: Cancer Network)
Source: Cancer Network - February 22, 2013 Category: Cancer & Oncology Source Type: news

ImmunoGen, Inc. Announces FDA Approval Of Kadcyla (Ado-Trastuzumab Emtansine; Also Known As T-DM1)
ImmunoGen, Inc ., a biotechnology company that develops anticancer therapeutics using its TAP technology, recently announced that Roche has reported that the U.S. Food and Drug Administration (FDA) has granted marketing approval to Kadcyla for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), The First Antibody-Drug Conjugate For Treating HER2-Positive Metastatic Breast Cancer
Genentech, a member of the Roche Group recently announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla(ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 22, 2013 Category: Pharmaceuticals Source Type: news

Is Lapatinib an Option When Trastuzumab Is Not?Is Lapatinib an Option When Trastuzumab Is Not?
Globally, trastuzumab is not always available for women with HER2+ breast cancer. Dr. Lidia Schapira reports on a study that looks at the potential benefit of oral lapatinib after primary therapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 19, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Dako Receives FDA Approval For Fast, Accurate, Nontoxic FISH Assay For Cancer Diagnostics
Dako, an Agilent Technologies Company, has introduced IQISH technology in the United States. The technology will reduce the turnaround time for cancer evaluation from two days to three and a half hours. This will ease the waiting time and associated anxiety for the patient and allow physicians to more quickly initiate targeted cancer treatments. HER2 IQFISH pharmDx, a fluorescence in situ hybridization (FISH) assay, is the first product approved by the U.S. Food and Drug Administration that uses the Dako IQISH technology, which is based on Dako's fast IQISH hybridization buffer chemistry... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 19, 2013 Category: Consumer Health News Tags: Medical Devices / Diagnostics Source Type: news

Draft NICE guidance recommends use of Oncotype DX to guide early breast cancer treatment decisions
Source: NICE Area: News NICE has issued its third diagnostics consultation on gene expression profiling and expanded immunohistochemistry (protein expression profiling) tests to guide the use of adjuvant chemotherapy in early breast cancer management (MammaPrint, Oncotype DX, IHC4 and Mammostrat). These tests measure multiple markers within the tumour that may indicate how the tumour is likely to develop. This third consultation follows consultations on previous drafts and the submission of a confidential access proposal by the manufacturer of Oncotype DX.   The draft guidance recommends the use of Oncotype DX in...
Source: NeLM - News - February 18, 2013 Category: Drugs & Pharmacology Source Type: news

Finding Common Regions of Alteration in Copy Number Data
In this chapter, we review some recent methods designed for detecting recurrent copy number regions, that is, genomic regions that show evidence of being altered in a set of samples. We analyze Affymetrix SNP6 data from 87 Her2-type breast tumors from a recent study using three different methods, showing different definitions and features of common regions: studying heterogeneity in copy number profiles, refining candidates for driver oncogenes, and consolidating broad amplifications. (Source: Springer protocols feed by Genetics/Genomics)
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Nonfamilial Breast Cancer Subtypes
Over the last decade, our knowledge in somatic genetic events related to breast cancer has increased ­enormously. Through usage of various genome-wide molecular approaches, it has become increasingly clear that breast cancer is a vastly heterogeneous disease. Microarray-based gene expression profiling has divided breast cancer into five distinct intrinsic subtypes termed basal-like, HER2-enriched, normal-like, luminal A, and luminal B. Importantly, these subtypes are closely correlated to clinical variables as well as different outcomes, with luminal A tumors as the good prognostic group. Initial studies using genome-w...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Diversity of Triple-Negative Breast Cancer Complicates Treatment
Treatment of triple-negative breast cancer, so named because it lacks estrogen receptors, progesterone receptors, and HER2 overexpression, is one of the most challenging areas of breast oncology. Not only... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 14, 2013 Category: Cancer & Oncology Source Type: news

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab (BIG 1-01)
Source: Lancet Oncology Area: News Several randomised trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer but have identified CNS as the first site of relapse, possibly because trastuzumab does not adequately penetrate the CNS. To investigate further, researchers used data from the HERA trial to assess the frequency and course of CNS relapses, either as first event or at any time.   The HERA trial (BIG 1-01) is a large randomised phase 3 study comparing treatment with adjuvant trastuzumab after standard adjuvant chemotherapy for 1 year or 2 years with only...
Source: NeLM - News - February 13, 2013 Category: Drugs & Pharmacology Source Type: news

New Approach Mimicking The Body's Natural Defenses Could Help Treat A Therapy-Resistant Breast Cancer
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 9, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Some HER2-Negative Cancers May Benefit from Anti-HER2 Therapy
SAN ANTONIO (IMNG) - Some breast cancers categorized as HER2 negative by conventional testing harbor mutations that may still render them amenable to therapy targeting this receptor, researchers reported... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news

Phase II study of trastuzumab emtansine versus trastuzumab plus docetaxel for metastatic breast cancer
Source: JCO Area: News According to the results of a randomised Phase II study reported early online in the Journal of Clinical Oncology, first-line treatment of HER2-positive metastatic breast cancer (MBC) with trastuzumab emtansine (T-DM1) was associated with an improved progression-free survival (PFS) compared with trastuzumab plus docetaxel.   The authors note that trastuzumab plus taxane-based chemotherapy has been shown to be associated with improved outcomes versus chemotherapy alone in the first-line treatment of HER2-positive MBC. However MBC will eventually progress in most patients and chemotherapy-ass...
Source: NeLM - News - February 5, 2013 Category: Drugs & Pharmacology Source Type: news

Roche delivers strong 2012 results
Basel, 30 January 2013 Group sales rise 4%1 to 45.5 billion Swiss francs due to oncology sales, clinical laboratory business Core EPS 10% higher at 13.62 Swiss francs Operating free cash flow rises 10% to 15.4 billion Swiss francs HER2-franchise... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2013 Category: Pharmaceuticals Source Type: news

New Drug Application Filed for Antibody-Drug Conjugate
Trastuzumab Emtansine for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer (Source: Roche Investor Update)
Source: Roche Investor Update - January 29, 2013 Category: Pharmaceuticals Source Type: news

Resistance To Anti-HER2 Therapy In Breast Cancer Patients May Be Delayed By Treatment Targeting PI3K
Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens. The data, published in Cancer Research, a journal of the American Association for Cancer Research, indicated that failure of the anti-HER2 antibody trastuzumab to block HER2 from activating the phosphatidylinositol-3 kinase (PI3K) signaling pathway can lead to resistance to treatment... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 26, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

HER2 Status Best Predicts Benefit of Anti-HER2 Therapy
SAN ANTONIO (IMNG) - A variety of biomarkers failed to improve on the results of tumor HER2 status for predicting the benefits of therapy targeting HER2 signaling, based on an analysis of data from the... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 25, 2013 Category: Cancer & Oncology Source Type: news

Use IHC Assay First for HER2 in Esophageal Ca
SAN FRANCISCO (MedPage Today) -- Immunohistochemistry to assess HER2 status in esophageal cancer showed good sensitivity and specificity, suggesting potential to reserve a more costly test for indeterminate IHC results, according to a study reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 25, 2013 Category: Primary Care Source Type: news

HER2 status best predicts benefit of anti-HER2 therapy
Read the full story on MD Consult: HER2 status best predicts benefit of anti-HER2 therapy (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - January 25, 2013 Category: Journals (General) Source Type: news

Synthon Biopharmaceuticals Reports Positive Early Results With Its Second Generation HER2-Antibody-Drug Conjugate
Best-in-Class potential with improved therapeutic index compared to other armed antibodies Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs). In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon has reported complete tumor remission... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New Drug Target For Her-2 Related Breast Cancer
Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene promotes the progression and spread of breast cancer cells. The inactivation of a tumor suppression gene called Nischarin is among the mechanisms identified. The findings provide a new therapeutic target to block the function of Her2. The research was published in Cancer Research, OnlineFirst. About 30% of breast cancers are positive for the Her2 oncogene... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients
(American Association for Cancer Research) Early use of PI3K inhibitors may prevent or delay treatment resistance. Cancer cells resistant to anti-HER2 therapy had high levels of survivin. Newly identified biomarker may help predict anti-HER2 therapy resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 23, 2013 Category: Global & Universal Source Type: news

Synthon reports positive pre-clinical results from HER2-antibody-drug conjugate studies
Synthon Biopharmaceuticals has reported positive early pre-clinical results of its second generation HER2-antibody-drug conjugate (ADC). (Source: Drug Development Technology)
Source: Drug Development Technology - January 23, 2013 Category: Pharmaceuticals Source Type: news

LSUHSC research provides new drug target for Her-2 related breast cancer
(Louisiana State University Health Sciences Center) Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene promotes the progression and spread of breast cancer cells. The inactivation of a tumor suppression gene called Nischarin is among the mechanisms identified. The findings provide a new therapeutic target to block the function of Her2. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2013 Category: Global & Universal Source Type: news

TapImmune reports positive interim safety analysis in breast cancer study
Vaccine technologies company TapImmune has reported that positive interim safety analysis was achieved in breast cancer patients treated with HER2/neu antigens. (Source: Drug Development Technology)
Source: Drug Development Technology - January 11, 2013 Category: Pharmaceuticals Source Type: news

Bevacizumab plus paclitaxel vs. bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: phase III TURANDOT trial interim results
Source: Lancet Oncology Area: News Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine improves progression-free survival (PFS) and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. These two regimens were thus compared in an open-label, non-inferiority, phase III trial [TURANDOT (capeciTabine and bevacizumab Randomised Against avastiN anD taxOl Trial)].   The trial was designed to answer three main questions:   ...
Source: NeLM - News - January 10, 2013 Category: Drugs & Pharmacology Source Type: news

Direct Healthcare Professional Communication: Lapatinib combined with capecitabine has poorer efficacy compared with trastuzumab combined with capecitabine
Source: MHRA, GlaxoSmithKiline (GSK) Area: News GSK, in agreement with the European Medicines Agency and the MHRA has issued this communcation following the findings of two recent trials showing a statistically superior efficacy of trastuzumab- as compared with lapatinib-based regimens in certain settings. This effect was particularly pronounced in the patients who had no prior exposure to trastuzumab.   EGF111438/CEREBEL is a phase III trial comparing lapatinib in combination with capecitabine relative to trastuzumab in combination with capecitabine on the incidence of CNS as site of first relapse in women with ...
Source: NeLM - News - January 3, 2013 Category: Drugs & Pharmacology Source Type: news

Lapatinib benefits found for HER2-positive early-stage patients
Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology. (Source: MedWire News - Breast Cancer)
Source: MedWire News - Breast Cancer - December 17, 2012 Category: Cancer & Oncology Source Type: news

HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report
12/14/2012 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 14, 2012 Category: Urology & Nephrology Source Type: news